Faculty

Iman Abou Dalle
Lebanon

Bio
Assistant professor in hematology-oncology at the American University of Beirut medical center, and program director of the fellowship program. Graduated from the American University of Beirut then pursued two-year fellowship in leukemia at MD Anderson Cancer center in Houston,Texas. Dr. Abou Dalle authored and co-authored more than 50 publications in the last 5 years at peer reviewed journals of high impact in hematologic malignancies. She presented more than 20 abstracts at both national and international hematology meetings. Her main expertise is in hematologic malignancies, specifically in acute leukemias and myelodysplastic / myeloproliferative neoplasms.
Lionel Adès
France

Bio
Professor Lionel Adès is a hematologist based in Paris, France. He practices at Hôpital Saint-Louis and is Professor of Hematology at Université Paris Cité. His clinical and research expertise focuses primarily on acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). He has authored more than 250 peer-reviewed publications. His research has significantly advanced the understanding of disease biology, prognosis, and therapeutic strategies in MDS and AML.

He is a leading member of the Groupe Francophone des Myélodysplasies (GFM), the French cooperative group dedicated to improving diagnosis, management, and outcomes of MDS patients. At the European level, he plays an active role in the European Myelodysplastic Syndromes Cooperative Group (EMSCO), fostering international collaborations and contributing to the development of innovative therapeutic approaches. In addition, Professor Adès is closely involved with the Leukemia Institute Paris-Saint Louis (Institut Hospitalo-Universitaire), a major hub for research, innovation, and training in leukemia and pre-leukemic disorders.
Luca Arcaini
Italy

Bio
Farrukh Awan
USA

Bio
Farrukh Awan, M.D., is a Professor in the Department of Internal Medicine at UT Southwestern Medical Center and a member of the Division of Hematology and Oncology at UTSW’s Harold C. Simmons Comprehensive Cancer Center where he leads the Lymphoid Malignancies Program. He specializes in stem cell transplant, cellular therapies and evaluation of novel therapies for the treatment of patients with lymphoid malignancies and chronic lymphocytic leukemias.
Frederic Baron
France

Bio
Frédéric Baron received a medical degree from the University of Liège (Belgium) in 1997. He completed a residency in medicine and a competency in hematology at the University of Liège. He worked one year as a doctoral fellow at the Institut Gustave Roussy (IGR), Villejuif, France, in Salem Chouaib lab. He received a PhD degree from the University of Liège in 2001. His postdoctoral training included a 3-year fellowship at the Fred Hutchinson Cancer Research Center (FHCRC) in Seattle, WA, US, in Rainer Storb Lab. Dr. Baron joined the faculty at the University of Liège in 2007, and obtained a second thesis (“Agrégation de l’enseignement supérieur”) in Hematology in 2007. He is been senior research assistant at the National Fund for Scientific Research (FNRS) Belgium and the co-leader of the cord blood subcommittee of the ALWP of the EBMT.
Ali Bazarbachi
Lebanon

Bio
Ali Bazarbachi, MD, PhD is a Professor of Medicine (Hematology and Oncology), Professor of Anatomy, Cell Biology and Physiological Sciences, and Founding Director of the bone marrow transplantation program at the American University of Beirut-Medical Center. He received his MD and PhD degrees, residency and fellowship training at the University of Paris in France. Dr. Ali Bazarbachi’s basic and translational research focuses on targeted therapies for hematological malignancies as well as post-transplant pharmacological interventions. He has co-authored more than 400 articles in leading scientific journals including The New England Journal of Medicine, Science, Journal of Experimental Medicine, The Lancet Oncology, Journal of Clinical Oncology, Blood, Nature Communication, and Cancer Research. He is the Chairman of the EBMT Lymphoma Working Party, a cofounder of the International Academy for Clinical Hematology, past President and current Secretary General of the International Association for Comparative Research on Leukemia and Related Disorders, Chairman of the NCCN Lymphoma Group for Middle East and North Africa, the Chairman of the EMBMT Leukemia Working Party, past President of the Lebanese Society of Hematology, and Associate Editor of “Bone Marrow Transplantation”, “Clinical Lymphoma, Myeloma and Leukemia” and “Clinical Hematology International”. He garnered multiple prestigious national and international awards including the 2008 award of the French National Academy of Medicine, the 2022 King Hussein Lifetime Achievement Award for Cancer Research, and the Lebanese National Medal of Merit.
Didier Blaise
France

Bio
Prof Didier Blaise, MD: Aix Marseille Univ (AMU), Management Sport Cancer Lab (MSC EA4670<strong>) Institut Paoli Calmettes (IPC), Marseille, France is professor of hematology at Aix Marseille University. He is director of the transplant and cellular immunotherapy program at Institut Paoli Calmettes, Marseille. He has contributed to more than 550 peer reviewed publication. His major focuses are optimization of innovation in allogeneic transplantation, and social an economic evaluation of innovation.
Arthur Bobin
France

Bio
Côme Bommier
France

Bio
Dr. Bommier is a clinical hematologist at Hôpital St. Louis (Université Paris Cité, France) in the Hemato-Oncology department (Lymphoma/CLL unit), where he oversees the outpatient clinic, managing over 3,600 patients per year. From 2020 to 2023, he dedicated his PhD research to surrogate and prognostic endpoints in marginal zone lymphoma. He also spent a year at the Mayo Clinic (Rochester, MN) as a visiting faculty member, where he led research on real-world lymphoma cohorts. He is a member of the Lymphoma Study Association (LYSA) scientific committee and the Internation Extranodal Lymphoma Study Group (IELSG) in 2021. He is also leading the marginal zone lymphoma subgroup within the REALYSA study.
Uma Borate
USA

Bio
Dr. Uma Borate is a hematologist specializing in the treatment of clonal cytopenias, myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). She serves as an Associate Professor in the Division of Hematology at The Ohio State University and as the Acute Leukemia Clinical Research Disease Group Leader. Her clinical and translational research is on novel therapeutics in myeloid diseases, with a special focus in disease progression from cytopenia and early stage MDS to AML. She is the principal investigator for numerous investigator-initiated clinical trials based on laboratory science, studying novel combinations of targeted therapies for myeloid malignancies. She is also the national lead and site investigator for several early-phase, industry-supported MDS and AML studies in both upfront and relapsed/refractory disease. Her work has appeared in such peer-reviewed publications as Nature Medicine, Oncotarget, Blood Advances and Leukemia.
She has pioneered a myeloid malignancy predisposition clinic focusing on clinical care and research in patients at high risk for myeloid malignancies due to predisposing hereditary germline mutations and acquired mutations collectively known as the Hematologic Malignancies at Risk of Leukemic Transformation aka HALT program. She also leads a grassroots consortium that is made up of basic, clinical, translational, bioinformatics & industry experts across the world that focus on advancing research in clonal hematopoiesis (CH) and developing novel trials to prevent high risk CH progression to overt myeloid malignancies.
Additionally, she is involved in developing several protocols for the NCI cooperative groups in MDS and AML through the Myelomatch Initiative.
She is also a member of several professional organizations, including the Southwest Oncology and the Alliance Cooperative Groups, the American Society of Hematology, the American Society of Clinical Oncology and the American Association for Cancer Research. She feels privileged to be involved in the care of her patients and be a partner in their fight against their disease.
Eolia Brissot
France

Bio
Eolia Brissot, MD, PhD, is Professor of Hematology and works at Hematology and Cellular Therapy Department at the Saint-Antoine Hospital and Sorbonne University (Paris, France). She then undertook a PhD at Sorbonne University in Paris, France, before working at the laboratory of hematologic stem cell transplantation unit at the National Institute of Health, Bethesda, USA. She is Secretary of the ALWP of the European Society for Blood and Marrow Transplantation (EBMT). She has a special clinical and research focus on the development of GVHD prophylaxis, immunotherapy and different aspects of therapy of acute lymphoblastic leukemia. She has published more than 180 peer-reviewed articles in the field of stem cell transplantation, leukemia, and in different hematology and immunology journals.
Carmelo Carlo-Stella
Italy

Dr. Carmelo Carlo-Stella is currently Professor of Hematology at Humanitas University and Section Chief of the Lymphoma Unit at Humanitas Research Hospital in Milan. He also serves as Director of the Hematology Residency Program at Humanitas University.

His research focuses on the development of novel immunotherapeutic strategies for refractory lymphomas and on optimizing the clinical management of lymphoma patients through the use of circulating tumor DNA (ctDNA) profiling. His team applies multi-omics approaches to identify biomarkers of response and resistance to bispecific antibodies in relapsed/refractory large B-cell lymphoma.

Dr. Carlo-Stella serves on multiple advisory boards and is an active member of several professional societies. He has authored numerous original articles and reviews in leading peer-reviewed journals, including Blood, Journal of Clinical Oncology, The New England Journal of Medicine, Lancet Oncology, Clinical Cancer Research, and British Journal of Haematology. ORCID ID: 0000-0003-3144-0124.
Julio Chavez
USA

Bio
Julio Chavez is an Associate Member in the Department of Malignant Hematology and Cellular Immunotherapy, he’s also the ICE-T Clinical Research Medical Director of Hematologic Malignancies at H. Lee Moffitt Cancer Center and Research Institute as well as an Associate Professor of Hematologic Malignancies at University of South Florida in Tampa, Florida. He is focused on the treatment of B-cell malignancies, specifically Diffuse Large B-cell Lymphoma, Follicular Lymphoma, and Chronic Lymphocytic Leukemia. Has broad experience with Chimeric Antigen Receptor Therapy (CAR-T) and bispecific antibodies in lymphoma and leukemias. And currently has over 100 peer-reviewed publications in high-impact journals mainly in immunotherapy in lymphomas.
Fabio Ciceri
Italy

Bio
Fabio Ciceri is Director of Hematology and Bone Marrow Transplantation and Director of Comprehensive Cancer Center at San Raffaele Hospital. Since 2018 he is full professor of Hematology at the Vita-Salute San Raffaele University, where he also directs the residency school in Hematology. He graduated in Medicine and Surgery at the University of Pavia, and then specialised in Rheumatology at the University of Ferrara and in Hematology at the University of Milan. Professor Fabio Ciceri is active in the hematological field, where he deals with the treatment of acute leukaemia, aggressive lymphomas, myeloproliferative neoplasms, and hemoglobinopathies, contributing to the definition of both observational and prospective and interventional clinical studies. During his career he has developed advanced skills in the field of stem cell transplantation and gene therapy for the treatment of blood cancers, solid and non-neoplastic diseases such as autoimmune, neuroinflammatory, genetic diseases including hemoglobinopathies.He is past President of GITMO (Gruppo Italiano Trapianto Midollo Osseo, www.gitmo.it ) and Chair of Acute Leukemia Working Party of EBMT (www.ebmt.org ) and active member of expert groups including the Italian Society of Haematology (SIE), European Haematology Association (EHA), ERN-EuroBloodNet.He is consultant for many Pharma and Biotech companies for the development of new drugs and ATMPs.He is President of AISPO NGO (www.aispo.org) and active in health care cooperation projects in Africa and Middle East.
Ruth Clout
UK

Bio
Ruth Clout works at the Christie Hospital in Manchester, UK as the Lead nurse for haematology/transplant/CAR T education plus the inpatient unit. She has been working in Haematology and oncology for the past 22 years. She started in haematology at Guys Hospital London in 2000 and really found her love for haematology and transplant. She has worked as a sister on the inpatient haematology and transplant unit also working as a transplant coordinator and haematology day unit. In 2011 she commenced her current role. She has the pleasure of working with staff in both inpatient and outpatient facilities, clinically helping to support, guide and mentor in their professional development in many aspects of haematology, transplant, and CAR-T. She has an honorary teaching role at the University of Manchester where she is the course lead for the Principles of Haematology Module. She has also recently taken on the nurse roles for Cell Therapy and Immunobiology working party (CTIWP) as part of EBMT.
Thomas Cluzeau
France

Bio
Pr Thomas Cluzeau is MD, PhD and head of hematology department in CHU of Nice (member of Cote d’Azur University). Their main topics are myelodysplastic syndromes and acute leukemia (including myeloid and lymphoid). He performs basic and translational sciences in Mediterranean Center of molecular medicine (INSERM U1065), and with international collaborations (including Moffitt Cancer Center and Research Institute, Tampa, Florida, US). He is member of several french cooperative groups and is active in clinical research in French Group of myelodysplasia (GFM), Acute Leukemia French Association (ALFA) and Group for Research in Adult Lymphoblastic Leukemia (GRAALL).
Claire Copin
France
Roberto Crocchiolo
Italy

Bio
Roberto Crocchiolo is a medical doctor from Italy, specialized in Hematology in 2008. During years 2009-2015 worked as transplant physician in Italy and France, then joined the ASST Grande Ospedale Metropolitano Niguarda, Milano, in 2018. From the beginning os his activity, he participated to and conducted clinical and translational research projects mainly focused on transplant complications and immunogenetics. He is currently Adjunct Professor at the University of Milano-Bicocca and has authored or co-authored more than 130 peer-reviewed articles
Antonio Curti
Italy

Bio
Antonio Curti is Attending Physician at the Institute of Hematology “L.& A. Seràgnoli”, University-Hospital of Bologna, Italy. His research interests and activities include Basic and translational immunology of tumor escape mechanisms in leukemia, addressing the role of immunosuppressive microenvironment in leukemia development, Adoptive immunotherapy with alloreactive NK cells in acute myeloid leukemia patients as consolidation and MRD targeting strategy and Development of Phase 1, 2,and 3 clinical trials with innovative drugs in acute leukemia.
Moniek de Witte
Netherlands

Bio
Moniek de Witte is working as an MD-PhD in the department of hematology in the University Medical Center in Utrecht. She obtained her PhD in the lab of Professor Ton Schumacher at the Netherlands Cancer Institute, where she performed pre-clinical studies with engineered T cells. After her medical training to become a hematologist, she started her current position at the UMCU in 2013. In 2016 she did a post-doctoral fellowship at the University of Minnesota in the group of professor Jeff Miller. Both her scientific as well as her clinical work focusses on improving outcome for patients with myeloid malignancies and non-malignant disease. This includes the development of a stem cell transplantation platform based on ex vivo alpha-beta/CD19 depletion, a myeloablative conditioning regimen and personalized GVHD prophylaxis. She leads a research group of 2 PhD students, a master student and 3 data managers. In addition she has an active role within the Dutch SCT working party as well as EBMT.
Matteo Della Porta
Italy

Bio
My research interests mainly concern myeloid neoplasms (MN, including myelodysplastic syndromes, MDS; acute myeloid leukemias AML; and myeloproliferative neoplasms, MPN)

These investigations led to the identification of recurrent gene mutations in myelodysplastic syndromes. In particular, in 2010, I joined the International Cancer Genome Consortium Chronic Myeloid Disorders Working Group. This collaboration led to the identification of somatic mutations of SF3B1, a gene encoding a core component of RNA splicing machinery, in myelodysplasia with ring sideroblasts [N Engl J Med. 2011;365(15):1384-95]

I extensively studied the genotype-phenotype correlations of recurrent gene mutations in MN, and we found a close association between ring sideroblasts and SF3B1 mutations, which is consistent with a causal relationship. Moreover, we found that SF3B1 mutations were independent predictors of favourable prognosis, providing the first evidence that the identification of the mutant gene responsible for the initial clone in MN is relevant to clinical outcome. [Blood. 2011;118(24):6239-46, J Clin Oncol. 2013;31(28):3557-64; Blood. 2013 ;122(22):3616-27 Blood. 2015 Jul 9;126(2):233-41, Leukemia. 2015;29(1):66-75].

According to these progresses in defining the genomic landscape of MN, in recent years there was a shift from clinical and morphologic classification/prognostication schemes to those that are based on genomics which are closer to the disease biology and better capture clinical-pathological entities. In this context, by using advanced statistical models, we developed a proof of concept for the definition of a molecular classification of myelodysplastic syndromes [Nat Med. 2020;26(10):1549-1556; J Clin Oncol. 2021;39(11):1223-1233], thus providing evidence that MDS with SF3B1 and TP53 mutations are distinct disease entities.

In addition, my research activity showed that gene mutations may influence survival and risk of disease progression in MN, and that the evaluation of the mutation status may add significant information to currently used prognostic scores. In this context, we contributed to the definition of the new molecular prognostic score for myelodysplastic syndromes (Molecular International Prognostic Scoring System, IPSS-M) including both clinical and genomic features [NEJM Evid 2022;1(7)DOI:https://doi.org/10.1056/ EVIDoa2200008] and we provided an extensive validation of its prognostic value. [J Clin Oncol, 2023 in press]

In last years, as scientific and clinical coordinator of EU-funded initiatives (GenoMed4all – www.genomed4all.eu and SYNTHEMA – www.synthema.eu), I approached the study of Artificial Intelligence as a toll to improve personalized medicine in hematology. We developed solutions to improve clinical decision making process; in particular, we build decision models to better define candidate patients and optimal timing of stem cell transplantation, the only curative treatment for MN [J Clin Oncol. 2016;34(30):3627-3637; Leukemia. 2017;31(11):2449-2457; Lancet Haematol. 2023;10(2):117-28]

Overall, my research activity contributed to the development and clinical implementation of personalized medicine programs in MN, including improved disease diagnosis and classification, definition of optimal treatment and prediction of future outcomes.
Raynier Devillier
France
Amy DeZern
USA

Bio
Amy DeZern, M.D., M.H.S. Professor of Oncology, is the Vice Chair for Hematologic Malignancies (HM) in the Department of Oncology.

Dr. DeZern’s clinical expertise is in aplastic anemia, myelodysplastic syndromes, paroxysmal nocturnal hemoglobinuria, acute myeloid leukemia, and bone marrow transplantation.

Dr. DeZern received her medical degree at the Johns Hopkins University School of Medicine. She completed a residency in internal medicine at Johns Hopkins, followed by fellowships in medical oncology and hematology, and obtained a Master’s in Clinical Investigations at the Bloomberg School of Public Health.

As a clinical investigator with a focus on translation of novel treatments to the clinic, Dr. DeZern’s goal is to improve outcomes for patients with bone marrow failure at the bedside and in her research environment. Her principal research activities consist of designing and conducting clinical trials that test investigational new therapies and approaches in the treatment of bone marrow failure (aplastic anemia and myelodysplastic syndromes). She has specific expertise in the use of alternative donor bone marrow transplantation in patients with severe aplastic anemia and trials of novel therapeutics for patients with myelodysplastic syndromes. She has been the principal investigator for over 40 single-center and multicenter clinical trials in MDS and AA. Additionally, Dr. DeZern is the deputy co-chair of The National MDS Study. She is the Chair of working group 3 for the International MDS Guidelines, on the MDS guidelines for the NCCN, and was the 2023 Education Chair (Malignant Hematology) for the American Society of Hematology. Dr. DeZern is on the National Comprehensive Cancer Network (NCCN) Board of Directors as our clinical representative and is a member of the American Society of Hematology, the American Society of Clinical Oncology, and the American Society for Transplantation and Cellular Therapy. She was recently selected as a standing member of the FDA Oncologic Drugs Advisory Committee (ODAC.)
Jean El Cheikh
Lebanon

Dr. Jean El-Cheikh is an Associate Professor of Clinical Medicine and a bone marrow transplantation expert at AUBMC, one of the leading institutions in the Eastern Mediterranean region and one of 2 centers that offer BMT in Lebanon. Dr El-Cheikh received his MD from the University of Naples in Italy; followed by advanced training in Hematology with a special focus on Bone Marrow Transplantation (BMT) at the University of Bologna, Italy. He then moved to work as a faculty member (Praticien Hospitalier Specialist) at the Institute Paoli – Calmettes, Marseilles, France. In 2015 he moved to Lebanon and joined the NK Basile cancer center at the American University of Beirut Medical Center, (AUBMC). He has a distinguished reputation for his academic and scientific contributions to bone marrow transplants and targeted immunotherapies. Additionally, he possesses extensive experience in managing infectious diseases in patients with hematological malignancies. Dr. El-Cheikh holds an Executive Master’s Degree in Public Health from the University of Paris VII and a second Master’s Degree in Analysis and Management of Health Care Systems from ESA Business School, obtained in 2021. He is also a prolific author, with over 200 publications in prestigious international medical journals indexed in PubMed. His expertise is recognized through his role as a peer reviewer for numerous leading medical journals. An active researcher and global expert in malignant hematology, Dr. El-Cheikh is a member of several international scientific societies, including EHA, EBMT, ASH, ASBMT, EMBMT, SFH, and SFGMTC. He is the President and founding member of the Lebanese Adult Cancer Patients Association (REVIVE Association). Additionally, he is an active member of the Cancer Support Fund at the American University of Beirut and various other cancer support organizations. He also serves as Deputy of Doctors in Tripoli and the North of Lebanon.
Shannon Elf
USA

Bio
Naren Epperla
USA

Bio
Narendranath Epperla is an Associate Professor in the Division of Hematology and Hematologic Malignancies, Department of Medicine at the Huntsman Cancer Institute at the University of Utah. His research interests focus on conducting early phase clinical trials using novel drug combinations to treat patients with lymphoid malignancies as well as to identify possible biomarkers that can predict treatment response.
Andrew Evens
USA

Bio
Andrew M. Evens, DO, MBA, MSc is a hematology/oncology physician, cancer researcher, and healthcare executive who serves as the Deputy Director and Chief Physician Officer for Rutgers Cancer Institute and the Jack & Sheryl Morris Cancer Center, Associate Vice Chancellor for Clinical Innovation and Data Analytics with Rutgers Health, and System Director of Medical Oncology and Oncology Lead for RWJBarnabas-Rutgers Medical Group for the RWJBarnabas Health system. Dr. Evens is an international expert in lymphoid malignancies, with research interests including the study of novel therapeutic agents, predictive modeling, big data, and the implementation of personalized medicine. He is vice-chair of the Lymphoma Committee for the ECOG-ACRIN NCI research group; co-chair of the Big Ten Cancer Research Consortium lymphoma committee; the editor-in-chief of the British Journal of Haematology; vice-chair of the ASH Research Council Board of Directors; and Chair of the Scientific Advisory Board for the Lymphoma Research Foundation.
Thierry Facon
France

Bio
Thierry Facon, MD, is Professor of Haematology in the Department of Haematology, Lille University Hospital, Lille, France, a position he has held since 2000. Professor Facon received his MD at Lille University School of Medicine in 1987 and became Assistant Professor of Haematology at Lille University Hospital in 1989.

Professor Facon was President of the Intergroupe Francophone du Myélome (IFM) between 2003 and 2006, Vice-President of the French Society of Haematology between 2005 and 2013. Professor Facon has presented at several international congresses, including the Plenary session at the annual meeting of the American Society of Clinical Oncology (ASCO) in 2006, the Plenary sessions at the annual meeting of the American Society of Hematology (ASH) in 2013 and 2018 the Educational Session of European Haematology Association (EHA) in 2008 and 2014, and the Educational session of ASH in 2015 and 2018. He co-organized the XIIIth International Myeloma Workshop (IMW) in Paris in 2011, and is a member of the American Society of Hematology (ASH), the International Myeloma Working Group (IMWG), the International Myeloma Foundation (IMF). He is a founder member and administrator of the Fondation Française pour la Recherche contre le Myélome et les Gammapathies (FFRMG) under the aegis of the Fondation de France whose main objective is to enable scientists and students to carry out research programs in host laboratories in France or abroad.

He has presented the “Pierre Stryckmans Memorial Lecture” of the Belgian Hematological Society in 2015 and received the Joseph Michaeli Award from Weill Cornell Medicine, New York USA for his contributions to the treatment of Myeloma Research in 2017 and the International Myeloma Foundation Robert A. Kyle Life Time Achievement Award in 2020. He is an Honorary Professor at the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, China since 2015. Professor Facon is author and co-author of a number of articles and has published his work in various prestigious international journals including, as first or senior author, The Lancet and The New England Journal of Medicine.
Justin Ferdinandus
Germany

Bio
Dr. Justin Ferdinandus is a physician in the Department I of Internal Medicine at the University Hospital Cologne and a contributing member of the German Hodgkin Study Group (GHSG). His work within the GHSG involves the coordination of clinical trials with focus on advanced-stage Hodgkin Lymphoma, imaging biomarkers, fertility considerations, and analyses of health-related quality of life.
Sebastian Giebel
Poland

Bio
Prof. Sebastian Giebel is an internal medicine, hematology and clinical transplantation specialist. He is head of the Department of Bone Marrow Transplantation and Onco-Hematology in Maria Sklodowska-Curie National Research Institute of Oncology in Gliwice, Poland. Prof. Giebel is the President of the Polish Adult Leukemia Group (PALG) and vice-president of the Polish Lymphoma Research Group (PLRG), leader of ALL subcommittee of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT), member of the European Working Group for Adult Acute Lymphoblastic Leukemia. An author of over 300 scientific papers, mainly in the field of hematology and hematopoietic cell transplantation. In 2017 he was awarded Jedrzej Sniadecki Medal of the Polish Academy of Sciences, the highest national distinction in the field of medicine.
Anna Godfrey
UK

Bio
Anna Godfrey is a Consultant Haematologist in Cambridge, UK, with interests in myeloproliferative neoplasms and diagnostic haemato-oncology. She is Clinical Lead for the Cambridge Haematopathology and Oncology Diagnostics Service which provides haematopathology provision to the East Anglia region. Her PhD is in the biology of JAK2-positive myeloproliferative neoplasms and she is principal investigator and/or co-investigator for a number of MPN clinical trials.
Hildegard Greinix
Austria

Bio
Prof. Hildegard T. Greinix,
Medical University of Graz, Austria

I have a long-standing research interest in allogeneic hematopoietic cell transplantation (HCT) including transplant immunology with acute and chronic graft-versus-host disease (GVHD) and induction of transplant tolerance. I am a participant in the NIH Consensus Development Project on chronic GVHD focusing on innovative treatments. My translational research projects have been focused on immune-based soluble and cellular biomarkers predictive and diagnostic for chronic GVHD. Another main preclinical and clinical research interest consists of the exploitation of immunotherapeutic strategies in hematologic malignancies including post-transplant cellular therapies. I am the Head of the Division of Hematology of the Medical University of Graz, Austria and I am the chair of the Austrian Stem Cell Transplant Group.
Mehdi Hamadani
USA
Alexandra Harrington
USA
Claire Harrison
UK
Florian Heidel
Germany

Bio
Olivier Hermine
France

Bio
Olivier Hermine MD, PhD is a professor of hematology at the University of Paris Cité, head of the clinical department of hematology and national reference center on mastocytosis at the Hospital Necker Enfants-Malades. He is also head of a research group on physiopathology and treatment of hematological disorders at the Imagine Institute and founder and coordinator of the laboratories of excellence on red cells in France. He is current member of the American Society of Hematology and active member of the Red cell committee. He is a board member of EBMT Lymphoma working group and chairman of the Mantle cell sub-committee, European Mantle cell network, member of the scientific and administrative committee and coordinator of the Mantle cell group of the LYSA (French Lymphoma study group), and of the international retrovirology association (IRVA; HTLV-1 and related virus including T cell lymphoma) and co-founder and scientific director of the French CELAC group on Intestinal Lymphoma. He is elected member of the French national academy of science, French national academy of pharmacy, Belgium Royal academy of medicine, and of Academia Europa of medicine. He teaches hematology both basic and clinical at different levels from undergraduate to MD and PhD. He is a board member of Imagine Institute. He is co-author of more than 965 publications in International Scientific Journals. He is co-founder and scientific director of two biotechnologies (Inatherys (monoclonal antibodies against Transfeerin receptor in hematological malignancies) and AB Science (kinase inhibitor). With AB science he pioneered the development of the first kinase inhibitor in mastocytosis in dogs, cats and humans. Overall his research tries to understand and study mechanisms underlying several haematological malignancies and benign hematological disorders in humans and animals, in order to improve care and develop targeted and immune therapies.
Ernst Holler
Germany

Bio
Prof Dr E Holler was trained in hematology and stem cell transplantation under the supervision of Prof Hans Hochem Kolb at the LMU Munich from 1980 until 1998. He has been the head of the clinical allogeneic transplant program at the University Hospital of Regensburg (UKR) from 1998 until his retirement as a clinical physician in 2019. He now has the position of a Senior Professor on translational research in allogeneic stem cell transplantation at the UKR. He has published more than 350 peer reviewed manuscripts with focus on acute and chronic GvHD. His actual research focusses on biomarkers of GvHD and the role of microbiota in complications of allogeneic SCT and immunoregulation.
He Huang
China

Bio
He Huang, M.D., Ph.D., Director of Bone Marrow Transplantation Center of The First Affiliated Hospital, Zhejiang University School of Medicine; Director of Hematology Institution of Zhejiang University. Prof. Huang specializes in clinical and basic research on hematopoietic stem cell transplantation, cellular immunotherapy and stem cell biology research. As corresponding author, he has published 307 original papers in SCI-cited journals including New England Journal of Medicine, Nature, Cell Research, Lancet Haematology, Cell Metabolism etc. For his outstanding achievement on hematopoietic stem cell transplantation, Prof. Huang was awarded the national prizes by State Council twice in 2003 and 2015, respectively.
Susanne Isfort
Germany

Bio
Tania Jain
USA

Bio
Tania Jain a physician scientist in the hematological malignancies and stem cell transplantation division with Sidney Kimmel Comprehensive Cancer Center at the Johns Hopkins and my academic focus is cellular therapy and transplantation in the treatment of high-risk hematological malignancies with a disease focus on myeloproliferative neoplasms. In my role as clinical investigator, I initiate and conduct clinical trials involving novel agents in MPNs and position the role of treatments to improve transplantation outcomes.
Mohamed Kharfan-Dabaja
USA
Shahram Kordasti
UK

Bio
Following his graduation from medical school and clinical training in Internal Medicine/Haematology, Dr Kordasti received his MSc in Medical Immunology and PhD in Cancer Immunology from King’s College London. He is currently a reader (Associate Professor) in Applied Cancer Immunopathology at King’s College London. He is also a clinical haematologist at Guy’s Hospital, and he has an interest in MDS, AA, and myeloproliferative neoplasms (MPN). His main research interest lies in the plasticity of CD4+ T cells, their interaction with the inflammatory microenvironment, and their role in the immunobiology of myeloid malignancies. Another focus of his research group is computational biology, multidimensional cytometry, and integrating multiomics data for patient stratification. Additionally, he leads an international consortium, i4MDS, focusing on standardising immune monitoring in patients with MDS.
Jurgen Kuball
Netherlands

Bio
Prof. Dr. Jürgen Kuball chairs the Department of Hematology at the UMC Utrecht Cancer Centre. Clinical activities focus around acute leukemia and allogeneic stem cell transplantation and he is medical director of the stem cell transplantation program. His research activities focus around tumor immunology and the ATMP development of a next generation of engineered immune cells. Within this context he is scientific co-founder of the UMC Utrecht spin-off company GADETA and holder of multiple patents dealing with engineered immune cells. Kuball is also active member of EBMT and chairs since 2019 the Legal Regulatory Affairs Committee (LRAC) of EBMT.
Marco Ladetto
Italy

Bio
Marco Ladetto studied Medicine at the University of Torino (Torino, Italy, EU) and received his M.D. degree in 1992. From then on he worked in the onco-hematology field performing clinical activity, clinical research and translational research. In 1997 he got his post-graduate degree in hematology. He then worked at Dana Farber Cancer Institute Boston MA USA until early 1999 focusing on Minimal Residual Disease in mature lymphoid tumors. He then took the position of Assistant Professor in Hematology at the University of Torino. In 2014 he took a position of Head of Hematology Division at “Ospedale SS Antonio e Biagio” Alessandria, Italy. His main fields of interest are: diagnosis, prognosis and treatment of lymphoma, myeloma and chronic lymphocytic leukemia, minimal residual and other biological prognostic factors in mature lymphoid tumors. He is actively involved in the design of clinical trials in the context of Fondazione Italiana and European Mantle Cell Lymphoma Network. He has co-authored numerous scientific papers, book chapters, and abstracts in international peer-reviewed journals with an official H-index of 62. Past Head of the “Biological Studies Committee” and President elect Fondazione Italiana Linfomi (FIL). He has been Subject Editor for the Lymphoma Guidelines of the European Society of Medical Oncology (ESMO), and member of the European Hematology Association Clinical Guidelines Committee and ESMO Education Committee.
Xavier Leleu
France

Bio
Xavier Leleu is Professor, Head of the Myeloma Clinic and Head of the Department of Haematology at Hôpital La Mileterie . He collaborates closely with the Immunology fundamental lab U Inserm 1313, and heads the Thor axis early phase clinical research team at CIC U Inserm 1082. part of the academic hospital of Poitiers (Centre Hospitalier Universitaire ), Poitiers, France.
Professor Leleu received his medical degree at the University of Bordeaux, France. He completed his specialisation in public healthcare and statistics at the University of Medicine of Paris, France and in haematology at the University of Medicine of Lille. Professor Leleu was the head of the Myeloma Clinic in Lille under Professor T Facon’s mentorship for almost 15 years. He received a Master’s degree in cellular biology at the University of Medicine of Lille in 2001 and completed his PhD in 2007, having studied at Dana Farber Cancer Institute, affiliated with Harvard Medical School, Boston, MA, USA. His main topic of research was the preclinical development of novel agents and understanding mechanisms of resistance and of dormancy in Waldenström macroglobulinaemia and the clinical development of novel agents in multiple myeloma in the context of the most recent discoveries in the biology of myeloma. He was trained with his mentors Dr IM Ghobrial and Dr SP Treon in Prof. Kenneth
Anderson’s laboratory.
Pr Leleu is a member of the IFM ( Intergroupe Francophone of Multiple Myeloma), the treasurer and member of the board of director.
Professor Leleu’s current research is focused on treatment methods in multiple myeloma, incorporating emerging immunology and immunotherapy approaches to shift the future treatment paradigm to improve patient outcomes. Professor Leleu maintains a special interest in research relating to cure within the multiple myeloma field.
Nora Liebers
Germany

Bio
Stefano Luminari
Italy
Nicola Maciocia
UK

Bio
Dr Nicola Maciocia is an Honorary Consultant Haematologist at UCLH specialising in cellular therapies and bone marrow transplantation. She undertook medical training at the University of Edinburgh followed by haematology sub-specialty training at UCLH.

She is a Clinician scientist specialising in CAR-T cell therapies for blood cancer. She completed her PhD in CAR-T cell therapy for T cell acute lymphoblastic leukaemia in the laboratory of Dr Martin Pule at UCL in 2022 and is currently an NIHR funded academic clinical lecturer in the UCL CAR-T cell programme.
Florent Malard
France

Bio
Florent Malard, MD, PhD, studied medicine at the University of Nantes, France and obtained his PhD degree at Sorbonne Université in Paris, France, followed by a postdoctoral fellowship at the Memorial Sloan Kettering Cancer Center, New York, USA. He is now appointed as a Professor of Hematology at Sorbonne Université and Saint-Antoine Hospital, Paris, France. His research works focused on allogeneic hematopoietic cell transplantation, immunology, microbiota and multiple myeloma. He has published so far over 100 publications on these topics.
Ludovic Martinet
France

Bio
Ludovic Martinet is Research Director at INSERM and co-leads the Genomics and Immunology of Myeloma (GENIM) team at the Cancer Research Center of Toulouse (CRCT). His group is dedicated to understanding the genomic complexity and immune dysfunctions that drive multiple myeloma progression and treatment resistance. He has developed a strong expertise in single-cell and multi-omic approaches to dissect the tumor–immune microenvironment, and in translational research bridging fundamental discoveries with clinical applications. His team is actively involved in collaborative national and international projects, integrating genomic profiling, immune monitoring, and innovative therapeutic strategies. A major focus of his work is the development and preclinical evaluation of immune-based therapies, including CAR T cells, bispecific antibodies, and novel combination strategies. Through these efforts, his research aims to improve precision medicine approaches and design more effective treatments for patients with multiple myeloma
John Mascarenhas
USA

Bio
Dr. John Mascarenhas is a Professor of Medicine at the Icahn School of Medicine at Mount Sinai (ISMMS) and a member of the Tisch Cancer Institute in New York City. He is the Director, Center of Excellence in Blood Cancers and Myeloid Disorders, Director of the Adult Leukemia Program, and Leader of Clinical Research within the Myeloproliferative Disorders Program at Mount Sinai. Additionally, he serves as the Principal Investigator of the clinical trials project within the National Cancer Institute sponsored Myeloproliferative Neoplasms Research Consortium (MPN-RC).
Christine Mauz-Körholz
Germany

Bio
Christine Mauz-Körholz is a Pediatric Oncologist and an Associate Professor of Pediatrics. She is the Director of the pediatric Stem Cell transplant Program, is head of the Pediatric Hodgkin Lymphoma Trial office in Giessen, Germany, Chairperson of the German Pediatric Hematology/Oncology Society’s Hodgkin Committee (GPOH-HD) and Scientific Secretary of the European Network for Pediatric Hodgkin Lymphoma (EuroNet-PHL) trial consortium. For more than two decades, her research has focused on conducting clinical trials for optimizing treatment and lowering treatment burden in children and adolescents with Hodgkin lymphoma. The main goal of the contemporary Hodgkin lymphoma trials is to significantly lower treatment toxicity for avoiding late effects in later life of Hodgkin lymphoma survivors, namely reduce radiotherapy burden to limit the rate of second malignancy and to eliminate gonadotoxic agents to preserve fertility in those young Hodgkin lymphoma survivors with childbearing potential. Together with Prof. Monika Metzger, St Jude Children’s Research Hospital, Memphis, TN, USA, Prof.. Mauz-Körholz has founded a global platform, the International Symposia for Childhood, Adolescent and Young Adult Hodgkin Lymphoma (ISCAYAHL). These conferences take place every two years and serve as a major forum for the Pediatric Hodgkin lymphoma community, globally. Another important initiative has been started, the “Staging-Evaluation-and Response-Criteria-Harmonisation-Initiative (SEARCH for CAYAHL). Thereby, the comparability of clinical trials not only among pediatric consortia but also between pediatric and adult trial consortia should eventually be possible; which is of tremendous value for trials with novel agents. She has 155 peer-reviewed publications in international medical science journals.
Donal McLornan
UK

Bio
Dr Donal McLornan works as a consultant in the MPN, allogeneic transplant and CAR-T team at University College London Hospital, which has the largest transplant and academic CAR T program in the UK. He is the current chair of the Chronic Malignancy Working Party of the EBMT and is co-chair of the scientific council. Additionally, he is the vice chair of the Global Outreach Committee of EHA and chairs the UK wide Clinical Trial MPN group. He has a particular interest in MPN, MPN/MDS overlap and allogeneic stem cell transplantation. His research and clinical trial portfolio focuses on Myelofibrosis and blast phase disease and he has published widely on these topics.
Mary Frances McMullin
UK

Bio
Professor Mary Frances McMullin trained in Haematology in N. Ireland and The Royal Postgraduate Medical School, Hammersmith hospital, London. She was appointed senior lecturer in haematology in QUB in 1991 and consultant haematologist and proceeded to Professor of Haematology in 2006. Her clinical and research interests include myeloproliferative neoplasms, investigation of the rare congenital erythrocytosis, and acute myeloid leukaemia. She has published extensively in the area.
Adam Mead
UK

Bio
Adam Mead is a professor of haematology in the University of Oxford. Professor Mead is the Clinical Lead for Myeloproliferative Neoplasms (MPN) at Oxford University Hospitals NHS Foundation Trust and has been the Principal or Chief Investigator of over 50 clinical trials in MPN and chronic myeloid leukaemia (CML). He chaired the National Cancer Research Institute MPN subgroup from 2016 to 2022. Professor Mead’s leads a research group at the MRC Weatherall Institute of Molecular Medicine. The overarching focus of his research group is to discover novel and rational therapeutic strategies to address the current unmet need in persons with MPN, fuelled by a better understanding of the biological principles underlying disease development and progression. His work using cutting edge techniques in single cell genomics and experimental models has revealed hitherto unrecognised heterogeneity of cancer stem cells in MPN, including a key role for inflammation in promoting therapy resistance and genetic evolution.
Ruben Mesa
USA
Mohamad Mohty
France
Julia Montoro
Spain

Bio
Dr. Julia Montoro (MD, PhD) is a hematologist with a special interest in patients with Myelodysplastic Syndromes (MDS) and Hereditary Predisposition Hematological Neoplasms at Vall d’Hebron University Hospital in Barcelona, where she has been working since 2013.
She graduated in Medicine in 2008 and completed her medical training between 2009 and 2013 in the Department of Hematology at Vall d’Hebron University Hospital. During this period, she carried out her Research Proficiency Thesis titled “Causes of Death in Patients with Myelodysplastic Syndrome.” She was awarded the Research Promotion Grant from the Spanish Society of Hematology and Hemotherapy (SEHH) for two consecutive years (2014-2015) for the project “Evaluation of the Impact of Autoimmune Disorders in Patients with Myelodysplastic Syndrome.”
From August 2016 to December 2017, she undertook a fellowship in the Basic and Translational Research Laboratory at the Herbert Irving Cancer Center of Columbia University in New York, under the supervision of Dr. Azra Raza, an internationally recognized expert in the field of MDS. During this period, she received a grant from the CRIS Foundation to develop the project “Predicting Response to Luspatercept in Myelodysplastic Syndromes: Analysis of Terminal Erythroid Differentiation Using an Ex Vivo System and RNA Sequencing.”
She completed her doctoral thesis in September 2019 with the highest distinction, Cum Laude, for her dissertation titled “Improvement of Prognostic Assessment Strategies in Patients with Myelodysplastic Syndromes,” which resulted in two first-author publications. Additionally, throughout her career, she has co-authored numerous clinical publications and delivered multiple oral presentations at national and international conferences, both as a co-author and as a lead author.
Dr. Montoro is a member of the Vall d’Hebron Institute of Oncology (VHIO), an internationally renowned cancer research institution. She is also a member of the Spanish Society of Hematology and Hemotherapy (SEHH), the European Hematology Association (EHA), the Spanish Group of Myelodysplastic Syndromes (GESMD), and serves as President of the Catalonia-Balearic Group of Hereditary Predisposition Hematological Neoplasms.
Since January 2021, she has been the coordinator of the Hematological Genetic Counseling Unit at Vall d’Hebron University Hospital, focusing on Myeloid Neoplasms with Hereditary Predisposition and patients with Clonal Hematopoiesis of Indeterminate Potential.
Talha Munir
UK
Arnon Nagler
Israel

Bio

Professor Arnon Nagler, MD, MSc
Chaim Sheba Medical Center, Israel

– Director of the Division of Hematology, Chaim Sheba Medical Center, Israel
– Director of Bone Marrow transplantation and Cord Blood Bank, Chaim Sheba Medical Center, Israel
– Professor of Medicine at the Tel Aviv University, Tel Aviv, Israel
– One of the pioneers of the non-myeloablative and reduced intensity/toxicity allogeneic transplantations for both malignant and non-malignant disorders (Blood 1998)
– Established the first public cord blood bank and performed the first cord blood transplanataion in Israel
– Leader of the Alternative donor subcommittee of the ALWP of the EBMT from 2008-2010
– Leader of the RIC subcommittee of the ALWP of the EBMT – since 2010
– Serves on the Editorial Board of several BMT and Hematology Journals and is a Section Editor for Leukemia
– Chair of the Acute Leukemia Working Party (ALWP) of the EBMT

Dr Nagler received his medical training at the Hebrew University-Hadassah Medical School, Jerusalem, Israel; he then carried out a Postdoctoral research fellowship in hematology and bone marrow transplantation at “Stanford University Hospital” Palo Alto, CA, in the USA, from 1986 to 1990.
Dr Nagler serves on the Board of Directors of Netcord organization of cord blood banks and was the Netcord Threasurer from 2010-2013.
Dr Nagler has received several awards including the best scientific abstract award of the ASBMT/CIBMR Tandem meeting (2004) and the best clinical abstract award of the NMDP Council Meeting (2004). In addition, Dr Nagler is a popular speaker and has made numerous, invited, international presentations and many Oral presentations on almost annual basis in all international transplantation and hematology meetings – ASH,ASBMT/CIBMTR, EBMT, EHA, Exp Hematology (including a presentation at the presidential symposium) and invited presentation at the Gordon conference (Boston USA).
Jessica Okosun
UK

Bio
Jessica Okosun is Professor of Translational Cancer Research at Barts Cancer Institute, Queen Mary University of London and a Consultant Haematologist at St Bartholomew’s Hospital. She leads a translational lymphoma research group in non-Hodgkin’s lymphomas, focussed on understanding biological heterogeneity and the development of disease- and treatment-biomarkers, using innovative technologies. She serves as a member of the UK Low and High Grade Lymphoma, Brain Lymphoma and Lymphoma Science subgroups. Professor Okosun leads the correlative research on several UK lymphoma clinical trials.
Astrid Olsnes
Norway

Bio
Francesco Onida
Italy

Bio
Francesco Onida is Associate Professor of Hematology in the Department of Oncology and Hemato-Oncology and Director of the Postgraduate School in Hematology at the University of Milan, Italy. He is Director of the Hematology and Bone Marrow Transplantation Unit, ASST Fatebenefratelli-Sacco, Milan, Italy. Professor Onida is also active member in the European Group for Blood and Marrow Transplantation (EBMT) Chronic Malignancies Working Party and Practice Harmonisation & Guidelines Committee (vice-Chair), in the MDS/MPN International Working Group, in the Italian Foundation for the study of Myelodysplastic Syndromes (FISM).

Professor Onida has been an invited speaker at numerous national and international meetings, including the EBMT and ASCO annual meetings. He is author of numerous peer-reviewed papers published in peer reviewed international journals.
Giorgio Orofino
Italy

Bio
Simona Pagliuca
France

Bio
Simona Pagliuca is a hematologist specialized in hematopoietic stem cell transplant and cellular therapies. After building her training in Italy (University Federico II of Naples), she served as Chef de Clinique Assistant from 2016 to 2019 in the Hematology and Transplant Unit at Saint Louis Hospital(Paris).She then spent two years of protected research time in the Translational Hematology and Oncology Research Department of Cleveland Clinic (Ohio, USA), developing expertise in immunogenetics and computational immunology applied to hematology. She obtained a PhD in hematology at the University of Paris in 2021. She is currently an Attending Physician at the Hematology Department of Nancy Hospital (France) and an Assistant Professor of Immunology at the University of Lorraine. Her research topics embrace multiple aspects of the immunological derangement of hematological malignancies and bone marrow failure disorders.
Laura Palomo
Spain

Bio
Dr. Laura Palomo worked for 9 years at the Josep Carreras Leukaemia Research Institute (IJC), where she completed her doctoral thesis in the MDS Group and subsequently continued as a postdoctoral researcher, always focusing her research on the molecular characterization of MDS and CMML. She then spent 3 years as a postdoctoral researcher in the Experimental Hematology Group at the Vall d’Hebron Institute of Oncology. In 2023 she joined the Laboratory of Hematology at the Catalan Institute of Oncology, as faculty in the Molecular Biology Unit. She is also a board member of the Spanish Group of MDS.
Sophie Park
France

Bio
Prof. Sophie Park is head of the Department of Hematology in Grenoble Alpes Hospital, France, where she became Professor of Hematology in 2013. After obtaining her medical degree, she became a fellow and then Associate Professor at Cochin Hospital, Paris, where she became board certified in 2003. She did a Postdoctoral Fellowship in Dominique Bonnet’s lab at Cancer Research UK, London, working on PDX murine models of AML.

Prof. Park’s research focuses on MDS and her clinical practice focuses on elderly acute leukemias and MDS. Prof. Park has been Chief Investigator in numerous Phase II/III studies of ESAs and iron overload in lower-risk MDS. She also leads translational research at the Institute for Advanced Biosciences, Grenoble, focusing on the role of the niche microenvironment, extracellular vesicles and miRNA in MDS pathophysiology, and has supervised numerous Masters and PhD students.

Prof. Park has delivered lectures and symposia at local, national, and international conferences and has authored book chapters, and articles published in the New England Journal of Medicine, Journal of Clinical Oncology, and Blood. She is a scientific board member for the Groupe Francophone des Myélodysplasies, of different scientific advisory boards in France and an advisory board member for drug manufacturers including Novartis, BMS, Pfizer.
Francesco Passamonti
Italy

Bio
Francesco Passamonti is full Professor of Hematology at the University of Milano Statale, Milano, and Head of Hematology at the Policlinico di Milano, Ospedale Maggiore, Fondazione I.R.C.C.S. Ca Granda, Milano Italy

He worked as full Professor at the University of Insubria of Varese and Head of Hematology at the Varese Hospital in Italy from 2010 to 2023, and as assistant Professor of Hematology and Hematologist at the University of Pavia in Italy from 1998 to 2010.

He is principal investigator in many clinical trials in hematological malignancies; however, his main area of interest is in the Philadelphia-negative myeloproliferative neoplasms (MPNs) polycythemia vera, essential thrombocythemia, and myelofibrosis. He collaborated to the definition of the molecular basis of MPNs and then designed new translational studies for their applications. He designed new prognostic models for essential thrombocythemia (IPSET), for primary (DIPSS) and post PV and post ET MF (MYSEC-PM) and defining effective responses to ruxolitinib treatment in patients with MF (RR6). He leads many clinical trials on the development of targeted therapies in MPNs. He participated as a panelist in the definitions of diagnostic criteria, response to treatments, and guidelines for informing treatment decision in MPN. More recently, he leaded the Italian Project on Covid-19 in hematological malignancies.

He is a member of the board of the International Working Group on Myeloproliferative Research and Treatment, as well as the European LeukemiaNet Work Package 9 for MPN and the MPN WP of the GIMEMA. Francesco Passamonti is a member of several hematology societies and Editorial Boards and is an invited speaker to several international meetings. He has authored and coauthored more than 300 articles on MPNs.
Naveen Pemmaraju
USA
Zinaida Perić
Croatia

Bio
Finn Petersen
Denmark

Bio
Lisa Pleyer
Austria

Bio
Lisa Pleyer is a full professor at Paracelsus Medical University Hospital Salzburg, Austria.

She is a board certified MD for internal medicine and hematology and oncology, with >10 years of experience in outpatient malignant and benign hematology.

Since 2011 she is the medical head of the advanced routine diagnostics laboratory and the stem cell laboratory of the 3^rd medical dept. at PMU Salzburg, where she is the scientific group leader and PI for myeloid malignancies

Completed university education in biomedical informatics with a focus on nanotechnology as well a master’s degree in business administration with a focus on international business aided in building the Austrian Myeloid Registry, which is a high granularity real world evidence data base documenting patients with myeloid neoplasias.
Emilie Poupardin
France
Bethan Psaila
UK

Bio
Beth is an Associate Professor of Haematology and Clinician Scientist at the University of Oxford. She leads a research programme in the MRC Weatherall Institute of Molecular Medicine, focused on applying innovative methods to understand disease mechanisms in myeloid blood cancers and bone marrow fibrosis, and studying normal and malignant megakaryocyte and platelet biology. Beth is an active clinician, contributing to a tertiary referral centre for the care of patients with myeloproliferative neoplasms, national treatment guidelines, and a growing portfolio of clinical trials, with a particular focus on the emerging immunotherapies for MPNs.
Marco Raddi
Italy

Bio
Deepti Radia
UK

Bio
Dr Deepti H Radia, Haematology Consultant, Guy’s & St Thomas’ Hospitals NHS Foundation Trust, London.UK.

Deepti Radia, MRCPI, FRCPath, MSc Med Ed.

Deepti has been in her consultant post since 2003 and the lead clinician for the systemic mastocytosis and chronic myeloid leukaemia services. The ECNM UK mastocytosis centre of excellence at Guys and St Thomas Hospitals was jointly established by Deepti and Dr Clive Grattan in 2005. This nationally recognised service accepts referrals from across the UK, Ireland and further afield.

She is CI for landmark trials for patients with advanced/indolent systemic mastocytosis – PKC412, EXPLORER, PATHFINDER,PIONEER & SUMMIT. She is a member of the study steering committee for the EXPLORER/PATHFINDER trials (Avapritinib in advanced SM) and APEX trial (Bezuclastinib) for patients with advanced SM.

Deepti is actively involved in the education of clinicians and patients improve understanding of mast cell disorders by delivering regular teaching in regional, national, international meetings in addition to the UKMasto.org and TMS patient support groups.
Shelisa Radjabaly
France
Andreas Reiter
Germany

Bio
Dr Andreas Reiter is an Associate Professor and Consultant of Hematology and Oncology at the Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Germany. Dr Reiter’s main research focus lies on pathogenesis, diagnosis and treatment of myeloproliferative neoplasms (MPN). Since 1992, he has been involved in translational research and numerous clinical trials, most recently particularly focusing on treatment of classic MPN and translational research for a better understanding of pathogenesis, diagnosis and treatment of eosinophilia-associated disorders and systemic mastocytosis. Dr Reiter has established a “German Registry for Disorders of Eosinophils and Mast Cells (GREM)”.
Daniel Royston
UK

Bio
Annalisa Ruggeri
Italy

Bio
Annalisa Ruggeri received her Medical degree from University of Messina, Italy, in 2004. She completed her Hematology residency at the San Raffaele Vita-Salute University, Milano, Italy in 2008, and the PhD in Hematology in 2014. She was staff member at the Hematology Department at the Saint Antoine Hospital in Paris, France and at Pediatric Hemato-oncology and cell and Gene therapy Department at the Ospedale Bambino Gesù in Roma, Italy. Since February 2020 she is senior physician at the Hematology and Bone Marrow Transplant unit of the San Raffaele Scientific Institute in Milano, Italy. She is active in clinical research activities being the scientific chair of the Eurocord office in Paris since 2012, and the current chair of the Cellular therapy and Immunobiology working party of the European society of Blood and Marrow transplantation (EBMT) since 2022. She is member of the ISCT- Stem cell source and graft engineering Committee. She is author of more than 200 peer-reviewed publications (H-index 52, Scopus) and has participated as invited speaker of many international conferences such American Society of Hematology (educational sessions), European society of Hematology and EBMT, ESH, ISCT, TCT.
Valeria Santini
Italy
Nicole Santoro
Italy

Bio
Dr. Nicole Santoro is a Medical Doctor and a Hematologist at the Hematology Unit, Department of Hematology and Oncology, “Santo Spirito” Civil Hospital, Pescara, Italy. In 2022 she completed the PhD in Clinical and Molecular Medicine at the University of Perugia mainly focusing her research on acute leukemia and bone marrow transplantation. She graduated Doctor of Medicine at “Gabriele d’Annunzio” University in 2011. From 2012 to 2017 she worked as a Resident in Hematology and Bone Marrow Transplantation at the University of Perugia. From September 2015 to April 2017 she had a fellowship in the Hematology Unit of the Hospital Saint Antoine in Paris.
Guy Sauvageau
Canada

Bio
Guy Sauvageau is the Principal Investigator of the Molecular Genetics of Stem Cells research unit at the Institute for Research in Immunology and Cancer (IRIC).His work emphasizes studying the molecular basis for self-renewal in hematopoietic normal cells and leukemia and his team identified several key genes that regulate HSC self-renewal. More recently, Guy Sauvageau’s team, in collaboration with Anne Marinier’s group at IRIC, discovered the small molecule UM171 that promotes the expansion of human cord blood-derived HSCs ex vivo. This breakthrough is being successfully translated to the clinic and UM171 is currently in several Phase II clinical trials.
Bipin Savani
USA

Bio
Dr Savani’s area of specialization is in the treatment of hematological malignancies, stem cell transplantation/ cellular therapy, and his primary field of research is in the long-term follow-up after transplantation/ cellular therapy, including regimen-related toxicity/ supportive care, and outcomes analysis of hematological malignancies, transplant and cellular therapy recipients. Dr Savani has published over 500 peer-reviewed articles, reviews, book chapters, editorials, perspectives and commentaries in the field of hematological malignancies, stem cell transplantation and cellular therapy. He is Co-Editor-in-Chief of journals Bone Marrow Transplantation (EBMT journal) and Clinical Hematology International (IACH journal) and associate editor of Journal of Transplantation and Cellular Therapy (ASTCT journal, formerly BBMT) and also serves as an editorial advisory board member for several journals in the field. Dr Savani is currently leader of the Conditioning Regimen Subcommittee of the Acute Leukemia Working Party of the EBMT. He also serves as the medical monitor for Blood and Marrow Transplant Clinical Trial Network (BMT-CTN). Dr Savani is a subcommittee member of the ASH Committee on Practice (COP).

Board Certifications: Internal Medicine (Exp 2025), Hematology (Exp 2027), Medical Oncology (Ext 2028)
Christoph Schmid
Germany

Bio
Dr. Schmid joined the group of Hans Kolb at the José Carreras Unit for hematopoietic stem cell transplantation in Munich in 1998. There, experimental and clinical studies on adoptive immunotherapy, as well as transplant strategies in high-risk leukemia were among his main areas of research. In 2005, he became head of the stem cell transplant unit at the university hospital of Augsburg, Germany, before he was appointed full professor for stem cell transplantation and cellular therapy research by the medical faculty at Augsburg University. For many years he has served as leader of the immunotherapy subcommittee of the EBMT Acute Leukemia Working Party. Currently, his major scientific interest is focused on biology, prevention and treatment of relapse after allogeneic SCT.
Hélène Schoemans
Belgium

Bio
Hélène Schoemans is a full staff member of the hematology department at the University Hospitals of Leuven, Belgium and an Assistant Professor at the Faculty of Medicine at KU Leuven.

In 2025, she became the Head of the HCT and CAR-T program at the University Hospitals of Leuven and serves as Survivorship Sub-committee Chair of the Transplant Complications Working party of the EBMT.

Her research and clinical interests include graft versus host disease (GVHD), eHealth, survivorship issues, quality of life (QoL), integrated care models and patient participation in research.
Bart Scott
USA

Bio
Bart Scott is a medical oncologist at Fred Hutchinson Cancer Research Center in Seattle, Washington. He is Professor of Medicine in the Division of Oncology at the University of Washington Medical Center. . Dr. Scott received his medical degree from the University of South Alabama. He then completed his internship and residency at the Johns Hopkins University School of Medicine in Baltimore, Maryland. He completed his fellowship in medical oncology at the University of Washington in Seattle. Dr. Scott has participated in a number of clinical trials involving myelodysplastic syndromes and myeloproliferative neoplasms. He has published numerous articles in journals such as American Journal of Medicine , Leukemia & Lymphoma , Blood , and Journal of Clinical Oncology . He was a co-author on the first edition of the NCCNN guidelines for MPN. He has served as an Associated Editor for Biology of Blood and Marrow Transplantation and is currently an Associate Editor for Leukemia. He is a member of the American Medical Association, the American Society of Hematology, the American Society of Clinical Oncology, and the Southwest Oncology Group, among many others.
Marie Sebert
France

Bio
Dr. Marie Sébert, MD, PhD. is a full Professor of Hematology at Saint-Louis Hospital, Université Paris Cité, and INSERM UMR1342, Paris, France. Dr. Sébert’s primary clinical research interests are focused on genetic predisposition to myelodysplastic syndromes (MDS) and acute myeloid leukemias (AML) and their clonal evolution. Dr. Sébert’s research also focuses on therapies for MDS/AML patients, she has been the principal investigator for several clinical trials of diagnostics and therapeutics of these disorders. She is an active member of national and international cooperative groups, especially the GFM (Groupe Francophone des Myelodsyplasies), the ALFA (Acute Leukemia French Association) and the EHA (European Hematology Association).
Roni Shouval
USA

Bio
Federico Simonetta
Switzerland

Bio
Dr. Simonetta is chef de clinique scientifique in Hematology at HUG, where he coordinates the CAR T cell program. After earning his MD in Genoa, he completed an MSc and PhD in Immunology in Paris, clinical training at HUG, and a postdoctoral fellowship at Stanford University. His research focuses on allogeneic cellular therapies, immune reconstitution, and biomarker discovery in hematologic malignancies and GvHD, supported by broad collaborations. He is co-chair of the EBMT CTIWP Immune Monitoring Subcommittee and serves on several Swiss and international boards on cellular therapies.
Alexandros Spyridonidis
Greece

Bio
Spyridonidis Alexandros was born in Greece and studied Medicine in Aristotle University of Thessaloniki, Greece. He completed his doctorate in Hematology and his specialization in Internal Medicine, Hematology and Oncology in University of Freiburg, Germany where he awarded the Venia Legendi (Privat Dozent) (1996-2005). He was appointed as Assistant Professor (2006) and promoted to Full Professor (2015) of Hematology in University of Patras, Greece where he established the JACIE-accredited Bone Marrow Transplantation Unit www.bmtpatra.gr, the first in Greece Centre of Bone Marrow Donor Volunteers CBMDP-Save a Life (www.xarisezoi.gr), the “Institute of Cellular Therapy” with the Eudra-GMP certified Labs www.ictpatras.gr and the MSc Program Cell and Gene Therapies: from Bench to Bedside and Good Manufacturing Practices www.mastercgt.com. He spent a research sabbatical at NIH, USA working on the clinical establishment of Cell Therapies (2012). The pipeline of his translational research includes the preclinical and clinical GMP-manufacture of academic Advanced Therapeutic Medicinal Cell Products (ATMPs), one of which is currently evaluated in a Phase I/II clinical study. In 2024 he was elected as Director of the FACT-accredited Hellenic Cord Blood Bank of the Biomedical Research Foundation of the Academy of Athens (BRFAA). He is/was Board Member of the “Hellenic Transplant Organization (HTO)”, the “Scientific Council of the Western Greece Prefecture”, the “Hellenic Society of Hematology” and the “Hellenic Society of Gene Therapy and Regenerative Medicine”. Outside Greece, he is/was Hellenic Representative in European Commission “Directorate Tissues and Cells”, co-Leader of the RIC-Committee of Acute Leukemia Working Party of EBMT, Board Member of the “Centre of the Study of Hematological Malignancies” Cyprus, JACIE Inspector for Cell Therapies (EBMT), scientific advisor of the Cord Blood Bank U Freiburg and Mentor at the H-Net Masterclass of the European Hematology Association (EHA). He has multiple publications, including a “How I treat” in Blood, and has received numerous honors and awards both national (e.g., Honor Award from HTO) and international (e.g., Van Bekkum Prize from EBMT) as well as multiple research grants in the field of leukemia and cellular therapy (e.g., EU-Hellenic Competitiveness Entrepreneurship Innovation, ELIDEK).
Maximilian Stahl
USA

Bio
Dr. Stahl is the Director of the Leukemia Program at Yale Cancer Center and the Chief of the Duffy Hematology Firm at Yale New Haven Hospital. He is also an Assistant Professor of Medicine at Yale University School of Medicine. His research focus is on early phase clinical trials in myeloid malignancies including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).

He authored and co-authored more than 130 peer reviewed publications and has presented his research in multiple national and international meetings. He has received the ASCO Conquer Cancer Foundation Young Investigator Award, the ASH HONORS Award, the Leukemia & Lymphoma Society Translational Research Program Award and several ASH Abstract Achievement Awards. He is a member of the Editorial Board of Leukemia & Lymphoma and serves as an ad hoc reviewer for several journals including Blood, Blood Advances, Leukemia, Clinical Cancer Research, the British Journal of Haematology and Haematologica.

He graduated from Hannover Medical School in Hannover, Germany. He then received his internal medicine residency training at the Yale School of Medicine where he also served as a chief medical resident. He then completed his Hematology and Oncology fellowship training at the Memorial Sloan Kettering Cancer Center. Subsequently, he was an Assistant Professor at Dana-Farber Cancer Institute and Harvard Medical School.
Anna Sureda
Spain
Cyrille Touzeau
France

Bio
Arjan van de Loosdrecht
Netherlands

Bio
A.A. van de Loosdrecht passed Medical School (cum laude) in 1989 at the VU University Medical Center in Amsterdam, The Netherlands. He received his PhD graduation (cum laude) in 1993 at the same University and graduated in Immunology in 1995. From 1993-1998 he followed clinical training in Internal Medicine followed by hematology at the Groningen University Medical Center, Netherlands. From 2000, he is a staff member and since 2012 a full professor of hematology at the department of Hematology, Amsterdam UMC. He is principal investigator of the preclinical and translational immunotherapy programs in AML and MDS. The major research lines focus on the immunopathogenesis of MDS/AML and on the development of leukemic dendritic cell vaccines for active specific immunization in patients with minimal residual disease (MRD). He is coordinator of HORIZON2020, AML-VACCiN program dealing with Dendritic Cell vaccination in AML. In MDS research focuses on the implementation of flow cytometry in MDS diagnosis and prognosis. He initiated a platform within the ELN on the implementation of flowcytometry in MDS. He is chair of the Database Sharing Committee of the International Working Group for Prognosis of MDS (IWG-PM) and board member of the Dutch HOVON working group on AML and MDS.
Umberto Vitolo
Italy

Bio
Umberto Vitolo, MD, is a Hematology Consultant and Head of Haematological Experimental Studies at the Candiolo Cancer Institute – FPO – IRCCS, Italy. Previously, he was Director of the
Hematology Unit at the University Hospital “Città della Salute e della Scienza” in Turin. He has also served as Professor of Hematology at the University of Turin since 2005.

Dr. Vitolo’s clinical expertise is centered on lymphoid malignancies, particularly aggressive and indolent lymphomas. He is actively involved in the development and coordination of national and international clinical trials on chemoimmunotherapy and novel therapeutic agents, including bispecific antibodies. Formerly President of the Italian Lymphoma Foundation, he remains on its board. He contributes to international guidelines (ESMO, EHA) and has authored over 300 peerreviewed publications.
Daniel Wiseman
UK

Bio
Dr Daniel Wiseman is an Honorary Consultant Haematologist and Physician Scientist at The Christie Hospital in Manchester, UK, specialising in myeloid malignancies. He leads the Christie’s myelodysplastic syndromes (MDS) service, is chief investigator on numerous clinical trials, and has contributed to several UK and international clinical guidelines. Until recently he was Translational Science lead for the UK NCRI MDS clinical studies group.

He runs a research lab at The University of Manchester, with a focus on understanding the biology of chronic myelomonocytic leukaemia (and related MDS/MPN overlap neoplasms), and developing new therapies for these challenging malignancies. He is a member of the International Working Group for MDS/MPN, with a leadership role in the multinational ABNL-MARRO basket trial.
Ibrahim Yakoub-Agha
France

Bio
Prof. Ibrahim Yakoub-Agha has elected President-Elect of EBMT. He’s the current chair of the EBMT practice harmonization and guidelines, past chair of the Chronic Malignancies Working Party (CMWP) of EBMT (2018-2022) and past President of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) (2012-2016).
He has contributed to the scientific community through his role as the Editor-in-Chief of “Current Research in Translational Medicine”. His research output includes authoring or co-authoring more than 650 scientific articles, with a primary focus on allogeneic hematopoietic cell transplantation and innovative gene and cellular therapy.
Amer Zeidan
USA
Lin Pierre Zhao
France

Bio